SG11201909499QA - Humanized antigen-binding domains against cd19 and methods of use - Google Patents
Humanized antigen-binding domains against cd19 and methods of useInfo
- Publication number
- SG11201909499QA SG11201909499QA SG11201909499QA SG11201909499QA SG 11201909499Q A SG11201909499Q A SG 11201909499QA SG 11201909499Q A SG11201909499Q A SG 11201909499QA SG 11201909499Q A SG11201909499Q A SG 11201909499QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- humanized
- car
- antibody
- domain
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 4
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
ESSENTIALACTIVATING DOMAIN:CDX W O 18/ 200 496 Al 5'LTR scFv CDS?, KIR CAR VECTOR CONSTRUCT TARGET BINDING DOMAIN: ANTIBODY DERIVED )scFv) HINGE RA.NSMEMBRANE DOMAIN COSTIMULATORY DOMAIN:CD28 CAR-ENGINEERED T CELL FIG. 1A (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ~ill IIIIIIIIIImillIVIIIIIIIHo o olo um Immo oimIE (10) International Publication Number WO 2018/200496 Al (51) International Patent Classification: A61P 35/02 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/029107 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/489,258 24 April 2017 (24.04.2017) US (71) Applicant: KITE PHARMA, INC. [US/US]; 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (72) Inventors: WILTZIUS, Jed, J.W.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). SIEVERS, Stuart, A.; c/o Kite Pharma, Inc., 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (74) Agent: BARBIC, Andrej et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: HUMANIZED ANTIGEN-BINDING DOMAINS AGAINST CD19 AND METHODS OF USE (57) : The invention provides a humanized anti-CD 19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD 19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD 19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells compris- ing the CAR or the TCR and their use in a T cell therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489258P | 2017-04-24 | 2017-04-24 | |
PCT/US2018/029107 WO2018200496A1 (en) | 2017-04-24 | 2018-04-24 | Humanized antigen-binding domains against cd19 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909499QA true SG11201909499QA (en) | 2019-11-28 |
Family
ID=62117162
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912400VA SG10201912400VA (en) | 2017-04-24 | 2018-04-24 | Humanized antigen-binding domains against cd19 and methods of use |
SG11201909499Q SG11201909499QA (en) | 2017-04-24 | 2018-04-24 | Humanized antigen-binding domains against cd19 and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912400VA SG10201912400VA (en) | 2017-04-24 | 2018-04-24 | Humanized antigen-binding domains against cd19 and methods of use |
Country Status (16)
Country | Link |
---|---|
US (2) | US10844120B2 (en) |
EP (2) | EP4286415A2 (en) |
JP (2) | JP6975841B2 (en) |
KR (3) | KR102481262B1 (en) |
CN (1) | CN110545883B (en) |
AR (1) | AR111418A1 (en) |
AU (2) | AU2018257894A1 (en) |
BR (1) | BR102018008260A2 (en) |
CA (1) | CA3060426A1 (en) |
ES (1) | ES2963598T3 (en) |
JO (1) | JOP20180042A1 (en) |
PT (1) | PT3615146T (en) |
SG (2) | SG10201912400VA (en) |
TW (1) | TWI768034B (en) |
UY (1) | UY37694A (en) |
WO (1) | WO2018200496A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2994829A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
EP3710471A1 (en) * | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
WO2020108090A1 (en) * | 2018-11-29 | 2020-06-04 | Zhejiang Ruijiamei Biotech Co., Ltd. | Car-t cells with humanized cd19 scfv with mutation in cdr 1 region |
CN109575143B (en) * | 2018-12-29 | 2022-06-17 | 博生吉医药科技(苏州)有限公司 | Bispecific CD20-CD19-CAR and application thereof |
CN109734813B (en) | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | Chimeric antigen receptor and application thereof |
EP3912992A4 (en) * | 2019-02-04 | 2022-11-23 | National University Corporation Ehime University | Car library and production method for scfv |
CN113710705B (en) * | 2019-03-05 | 2023-07-21 | 湖南远泰生物技术有限公司 | CAR-T cells with humanized CD19SCFV |
SG11202109057XA (en) * | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
AU2020270888A1 (en) * | 2019-04-08 | 2021-11-04 | Memorial Sloan Kettering Cancer Center | CD19 antibodies and methods of using the same |
EP4249075A3 (en) * | 2019-05-03 | 2023-11-08 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
CN112204135A (en) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | Immune cell expressing CD3 antibody receptor complex and application thereof |
WO2021004400A1 (en) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | Immune cell expressing cd3 antibody-receptor complex and use thereof |
CN111187352B (en) * | 2020-01-17 | 2020-11-03 | 南京蓝盾生物科技有限公司 | Chimeric antigen receptor targeting human CD19 and application thereof |
CN113307871B (en) * | 2020-02-27 | 2023-05-02 | 福州拓新天成生物科技有限公司 | Preparation and application of novel anti-CD 19 antibody and CD19-CAR-T cell |
IL295993A (en) * | 2020-03-03 | 2022-10-01 | Systimmune Inc | Anti-cd19 antibodies and methods of using and making thereof |
CN113402612A (en) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof |
CN111518219B (en) * | 2020-05-08 | 2021-06-22 | 浙江大学 | Chimeric antigen receptor, macrophage expressing same, method for regulating macrophage polarization and application |
US20230250188A1 (en) * | 2020-06-11 | 2023-08-10 | National University Corporation Kochi University | Humanized Anti-GPC-1 Antibody |
CN114163532A (en) * | 2020-09-10 | 2022-03-11 | 南京北恒生物科技有限公司 | Chimeric antigen receptor comprising novel costimulatory domains and uses thereof |
CN112375146B (en) * | 2021-01-07 | 2021-04-13 | 北京百普赛斯生物科技股份有限公司 | Anti-idiotypic antibody for detecting Anti-CD19 CAR expression level and application thereof |
CN114957481A (en) * | 2021-02-25 | 2022-08-30 | 华夏英泰(北京)生物技术有限公司 | Dual-target STAR for CD19 and CD22 |
WO2023208157A1 (en) * | 2022-04-29 | 2023-11-02 | 上海先博生物科技有限公司 | Cd19-targeting chimeric antigen receptor and use thereof |
WO2024020063A2 (en) * | 2022-07-19 | 2024-01-25 | La Jolla Institute For Immunology | Anti-hrf antibodies |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
KR20030032922A (en) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | Simultaneous stimulation and concentration of cells |
IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
CL2007003622A1 (en) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
EP2398829A2 (en) * | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
BR122021026173B1 (en) | 2010-12-09 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | PHARMACEUTICAL COMPOSITION |
EP2665521A4 (en) | 2011-01-18 | 2014-09-03 | Univ Pennsylvania | Compositions and methods for treating cancer |
AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
LT2956175T (en) | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
UY35468A (en) * | 2013-03-16 | 2014-10-31 | Novartis Ag | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER |
EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
AU2014296626B2 (en) | 2013-07-29 | 2019-03-07 | 2Seventy Bio, Inc. | Multipartite signaling proteins and uses thereof |
EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
JP6793902B2 (en) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | Adjustable chimeric antigen receptor |
CA2937750A1 (en) | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
TWI751102B (en) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | Antibodies and chimeric antigen receptors specific for cd19 |
CN107072184A (en) | 2014-09-19 | 2017-08-18 | 瑞泽恩制药公司 | Chimeric antigen receptor |
JP7098325B2 (en) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | CS1 targeted chimeric antigen receptor modified T cells |
US10493139B2 (en) * | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
EP3149046B1 (en) * | 2015-07-24 | 2020-02-26 | Innovative Cellular Therapeutics Co., Ltd. | Humanized anti-cd19 antibody and use thereof |
-
2017
- 2017-04-24 JO JOP/2018/0042A patent/JOP20180042A1/en unknown
-
2018
- 2018-04-24 US US15/961,562 patent/US10844120B2/en active Active
- 2018-04-24 BR BR102018008260A patent/BR102018008260A2/en unknown
- 2018-04-24 AU AU2018257894A patent/AU2018257894A1/en not_active Abandoned
- 2018-04-24 SG SG10201912400VA patent/SG10201912400VA/en unknown
- 2018-04-24 AR ARP180101041A patent/AR111418A1/en unknown
- 2018-04-24 JP JP2020507516A patent/JP6975841B2/en active Active
- 2018-04-24 KR KR1020227004726A patent/KR102481262B1/en active IP Right Grant
- 2018-04-24 PT PT187233200T patent/PT3615146T/en unknown
- 2018-04-24 WO PCT/US2018/029107 patent/WO2018200496A1/en unknown
- 2018-04-24 KR KR1020197034220A patent/KR102363742B1/en active IP Right Grant
- 2018-04-24 CA CA3060426A patent/CA3060426A1/en active Pending
- 2018-04-24 TW TW107113912A patent/TWI768034B/en active
- 2018-04-24 SG SG11201909499Q patent/SG11201909499QA/en unknown
- 2018-04-24 KR KR1020227044928A patent/KR20230006027A/en not_active Application Discontinuation
- 2018-04-24 UY UY0001037694A patent/UY37694A/en not_active Application Discontinuation
- 2018-04-24 EP EP23200491.1A patent/EP4286415A2/en active Pending
- 2018-04-24 CN CN201880026644.4A patent/CN110545883B/en active Active
- 2018-04-24 ES ES18723320T patent/ES2963598T3/en active Active
- 2018-04-24 EP EP18723320.0A patent/EP3615146B1/en active Active
-
2020
- 2020-11-10 US US17/094,335 patent/US20210061910A1/en active Pending
-
2021
- 2021-08-05 AU AU2021212061A patent/AU2021212061A1/en active Pending
- 2021-11-08 JP JP2021181622A patent/JP7434250B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3615146A1 (en) | 2020-03-04 |
SG10201912400VA (en) | 2020-02-27 |
WO2018200496A1 (en) | 2018-11-01 |
JP2020517302A (en) | 2020-06-18 |
CN110545883B (en) | 2024-04-02 |
KR20230006027A (en) | 2023-01-10 |
AR111418A1 (en) | 2019-07-10 |
US10844120B2 (en) | 2020-11-24 |
ES2963598T3 (en) | 2024-04-01 |
EP3615146B1 (en) | 2023-11-01 |
BR102018008260A2 (en) | 2020-04-28 |
TW202233691A (en) | 2022-09-01 |
TWI768034B (en) | 2022-06-21 |
CN110545883A (en) | 2019-12-06 |
JP2022028750A (en) | 2022-02-16 |
KR20190141211A (en) | 2019-12-23 |
KR20220025904A (en) | 2022-03-03 |
AU2021212061A1 (en) | 2021-08-26 |
EP4286415A2 (en) | 2023-12-06 |
US20180312588A1 (en) | 2018-11-01 |
PT3615146T (en) | 2023-11-27 |
US20210061910A1 (en) | 2021-03-04 |
UY37694A (en) | 2018-11-30 |
KR102481262B1 (en) | 2022-12-26 |
AU2018257894A1 (en) | 2019-10-31 |
TW201902928A (en) | 2019-01-16 |
CA3060426A1 (en) | 2018-11-01 |
JP7434250B2 (en) | 2024-02-20 |
JP6975841B2 (en) | 2021-12-01 |
JOP20180042A1 (en) | 2019-01-30 |
KR102363742B1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909499QA (en) | Humanized antigen-binding domains against cd19 and methods of use | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201903693QA (en) | Polypeptide variants and uses thereof | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods |